$RXRX
RECURSION PHARMACEUTICALS, INC. Stock $rxrx

$rxrx Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000160183022000012 Filed on March 23, 2022

Income Statement

Concept	2021	2020
Revenue	$10.18M	$3.962M
YoY Change	156.89%	70.85%
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$10.18M	$3.962M
YoY Change	156.89%
Gross Profit Margin	100.0%	100.0%
Selling, General & Admin	$66.67M	$27.04M
YoY Change	146.56%	35.88%
% of Gross Profit	655.05%	682.48%
Research & Development	$135.3M	$63.32M
YoY Change	113.63%	38.22%
% of Gross Profit	1329.05%	1598.16%
Depreciation & Amortization	$8.405M	$3.943M
YoY Change	113.16%	58.42%
% of Gross Profit	82.58%	99.52%
Operating Expenses	$193.0M	$88.58M
YoY Change	117.84%	36.78%
Operating Profit	-$182.8M	-$84.62M
YoY Change	116.01%	35.51%
Interest Expense	$2.952M	$1.360M
YoY Change	117.06%	114.17%
% of Operating Profit
Other Income/Expense, Net	-$3.704M	-$2.391M
YoY Change	54.91%	-525.44%
Pretax Income	-$186.5M	-$87.01M
YoY Change	114.32%	40.61%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$186.5M	-$87.01M
YoY Change	114.33%	40.61%
Net Earnings / Revenue	-1832.18%	-2196.01%
Basic Earnings Per Share	-$1.49	-$3.99
Diluted Earnings Per Share	-$1.49	-$3.99
COMMON SHARES
Basic Shares Outstanding	125.3M shares	21.78M shares
Diluted Shares Outstanding	125.3M shares	21.78M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$516.6M		$262.1M
YoY Change	97.09%		274.96%
Cash & Equivalents	$285.1M	$262.1M	$262.1M
Short-Term Investments	$231.4M		$0.00
Other Short-Term Assets	$9.066M	$2.155M	$7.200M
YoY Change	25.92%		12.5%
Inventory
Prepaid Expenses
Receivables	$34.00K	$156.0K	$200.0K
Other Receivables	$9.056M	$0.00	$0.00
Total Short-Term Assets	$534.7M	$266.4M	$269.5M
YoY Change	98.41%		252.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$64.72M	$25.97M	$26.00M
YoY Change	148.94%		6.56%
Goodwill		$801.0K
YoY Change
Intangibles		$1.689M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.716M	$650.0K	$700.0K
YoY Change	1145.14%		0.0%
Total Long-Term Assets	$75.63M	$32.15M	$29.10M
YoY Change	159.89%		16.4%
TOTAL ASSETS
Total Short-Term Assets	$534.7M	$266.4M	$269.5M
Total Long-Term Assets	$75.63M	$32.15M	$29.10M
Total Assets	$610.3M	$298.6M	$298.6M
YoY Change	104.4%		194.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.819M	$1.074M	$1.100M
YoY Change	156.27%		-15.38%
Accrued Expenses	$33.75M	$10.49M	$11.00M
YoY Change	206.81%		107.55%
Deferred Revenue		$10.00M
YoY Change
Short-Term Debt	$0.00		$0.00
YoY Change
Long-Term Debt Due	$90.00K		$1.100M
YoY Change	-91.82%		1000.0%
Total Short-Term Liabilities	$46.66M	$23.10M	$23.10M
YoY Change	101.98%		244.78%
LONG-TERM LIABILITIES
Long-Term Debt	$633.0K		$14.10M
YoY Change	-95.51%		13.71%
Other Long-Term Liabilities	$20.12M		$19.30M
YoY Change	4.23%		250.91%
Total Long-Term Liabilities	$20.75M		$33.40M
YoY Change	-37.88%		86.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$46.66M	$23.10M	$23.10M
Total Long-Term Liabilities	$20.75M		$33.40M
Total Liabilities	$67.41M	$56.56M	$56.60M
YoY Change	19.09%		130.08%
SHAREHOLDERS EQUITY
Retained Earnings		-$213.6M
YoY Change
Common Stock		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$542.9M	-$206.3M	$242.0M
YoY Change
Total Liabilities & Shareholders Equity	$610.3M	$298.6M	$298.6M
YoY Change	104.4%		194.48%

Cashflow Statement

Concept	2021	2020
OPERATING ACTIVITIES
Net Income	-$186.5M	-$87.01M
YoY Change	114.33%	40.61%
Depreciation, Depletion And Amortization	$8.405M	$3.943M
YoY Change	113.16%	58.42%
Cash From Operating Activities	-$158.6M	-$45.40M
YoY Change	249.38%	-20.41%
INVESTING ACTIVITIES
Capital Expenditures	$39.80M	$5.831M
YoY Change	582.52%	49.13%
Acquisitions	$0.00	$2.600M
YoY Change	-100.0%
Other Investing Activities	-$231.9M	-$2.910M
YoY Change	7870.65%
Cash From Investing Activities	-$271.7M	-$8.740M
YoY Change	3009.2%	123.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$12.80M	$77.00K
YoY Change	16520.78%	-99.31%
Cash From Financing Activities	$458.5M	$246.1M
YoY Change	86.3%	104.41%
NET CHANGE
Cash From Operating Activities	-$158.6M	-$45.40M
Cash From Investing Activities	-$271.7M	-$8.740M
Cash From Financing Activities	$458.5M	$246.1M
Net Change In Cash	$28.18M	$192.0M
YoY Change	-85.32%	222.91%
FREE CASH FLOW
Cash From Operating Activities	-$158.6M	-$45.40M
Capital Expenditures	$39.80M	$5.831M
Free Cash Flow	-$198.4M	-$51.23M
YoY Change	287.3%	-15.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001601830
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q4	us-gaap	Liabilities Liabilities	67407000	USD
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40323
CY2021	dei	Entity Registrant Name EntityRegistrantName	Recursion Pharmaceuticals, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4099738
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	41 S Rio Grande Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City,
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84101
CY2021	dei	City Area Code CityAreaCode	385
CY2021	dei	Local Phone Number LocalPhoneNumber	269 - 0203
CY2021	dei	Security12b Title Security12bTitle	Class A Common Stock, par value $0.00001
CY2021	dei	Trading Symbol TradingSymbol	RXRX
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	3900000000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	285116000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	262126000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1552000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	2000000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	156000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	9056000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	231446000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7514000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2155000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	534718000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	266437000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	8681000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3041000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64725000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25967000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1385000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1689000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	801000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	801000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	650000	USD
CY2021Q4	us-gaap	Assets Assets	610345000	USD
CY2020Q4	us-gaap	Assets Assets	298585000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2819000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1074000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32333000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10485000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10000000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10000000	USD
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	90000	USD
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1073000	USD
CY2021Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	1416000	USD
CY2020Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	467000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46658000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23099000	USD
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	4110000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2674000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6667000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16667000	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	633000	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	11414000	USD
CY2021Q4	rxrx	Lease Incentive Payable Noncurrent LeaseIncentivePayableNoncurrent	9339000	USD
CY2020Q4	rxrx	Lease Incentive Payable Noncurrent LeaseIncentivePayableNoncurrent	2708000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	56562000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	121434713	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	112088065	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	112088065	shares
CY2021Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	450850000	USD
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	448312000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2000000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	188400000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	170272462	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	170272462	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22314685	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22314685	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	943142000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7312000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400080000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213601000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-126000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	542938000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-206289000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	610345000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	298585000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10178000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3962000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2319000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	135271000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63319000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45809000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57682000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25258000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18951000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	192953000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	88577000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	64760000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-182775000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-84615000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-62441000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3704000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2391000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	562000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-186479000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-87006000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-61879000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.49
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.99
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.99
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.87
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125348110	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125348110	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21781386	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21781386	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21570265	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21570265	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-186479000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-87006000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-61879000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-162000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-36000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-186605000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87006000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61879000	USD
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	56413172	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	81194000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-63847000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-61879000	USD
CY2019	rxrx	Apic Share Based Payment Arrangement Option Early Exercise APICShareBasedPaymentArrangementOptionEarlyExercise	11000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	65000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1385000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	75189517	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	201109000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-124265000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-87006000	USD
CY2020	rxrx	Apic Share Based Payment Arrangement Option Early Exercise APICShareBasedPaymentArrangementOptionEarlyExercise	9000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	681000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4292000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	112088065	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	448312000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-206289000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-186479000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-126000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	462354000	USD
CY2021	rxrx	Temporary Equity Shares Conversion Of Convertible Securities TemporaryEquitySharesConversionOfConvertibleSecurities	112088065	shares
CY2021	rxrx	Temporary Equity Value Conversion Of Convertible Securities TemporaryEquityValueConversionOfConvertibleSecurities	448312000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6812000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14842000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	542938000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-186479000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-87006000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-61879000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8405000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3943000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2489000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	14842000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4292000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	1385000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	874000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-827000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-883000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-555000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4097000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-781000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-114000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	27000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5490000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1114000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-632000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10000000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	26667000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1745000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-185000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-340000	USD
CY2021	rxrx	Increase Decrease In Accrued Development Expense IncreaseDecreaseInAccruedDevelopmentExpense	561000	USD
CY2020	rxrx	Increase Decrease In Accrued Development Expense IncreaseDecreaseInAccruedDevelopmentExpense	1348000	USD
CY2019	rxrx	Increase Decrease In Accrued Development Expense IncreaseDecreaseInAccruedDevelopmentExpense	941000	USD
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	12764000	USD
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4123000	USD
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-798000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-158614000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45399000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57042000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39798000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5831000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3910000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2600000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	904000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	301137000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	69191000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2021	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	USD
CY2020	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	595000	USD
CY2019	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-271744000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8740000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3910000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	462901000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	239131000	USD
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	119915000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8437000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	681000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	65000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12798000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	77000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11183000	USD
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	11888000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6400000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	275000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	458540000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	246135000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120410000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28182000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	191996000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	59458000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267167000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75171000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15713000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	295349000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	267167000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75171000	USD
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	448312000	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	8071000	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2021	rxrx	Stock Issuance Costs Noncash StockIssuanceCostsNoncash	547000	USD
CY2020	rxrx	Stock Issuance Costs Noncash StockIssuanceCostsNoncash	547000	USD
CY2019	rxrx	Stock Issuance Costs Noncash StockIssuanceCostsNoncash	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	7749000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1400000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	680000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	989000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	485000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion Pharmaceuticals, Inc. (Recursion, the Company, we or our) was originally formed as a limited liability</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company on November 4, 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, we converted to a Delaware corporation and changed our name to Recursion Pharmaceuticals, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recursion is a biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. Recursion’s rich, relatable database of biological images generated in-house on the Company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had an accumulated deficit of $400.1 million. The Company expects to incur substantial operating losses in future periods and will require additional capital to advance its drug candidates. The Company does not expect to generate significant revenue until the Company successfully completes significant drug development milestones with its subsidiaries or in collaboration with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company or its partners need to complete clinical development and comply with comprehensive regulatory requirements. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as the uncertainty of clinical trial outcomes, uncertainty of additional funding and a history of operating losses. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded its operations to date through the issuance of convertible preferred stock (see Note 9, “Convertible Preferred Stock” for additional details) and the issuance of Class A common stock in an Initial Public Offering (IPO), which was completed in </span><span style="color:#1e1e1e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 10, “Common Stock” for additional details). Recursion will likely be required to raise additional capital. As of December 31, 2021, the Company did not have any unconditional outstanding commitments for additional funding. If the Company is unable to access additional funds when needed, it may not be able to continue the development of its products or the Company could be required to delay, scale back or abandon some or all of its development programs and other operations. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, could materially harm its business, financial condition and results of operations. </span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that the Company’s existing cash, cash equivalents and investments will be sufficient to fund the Company’s operating expenses and capital expenditures for at least the next 12 months.</span></div>
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400100000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP), which requires the Company to make estimates and assumptions that affect reported amounts and related disclosures. Actual results could differ from those amounts. Significant estimates and assumptions include the estimated progress towards the satisfaction of performance obligations to record revenue, accrued research and development expenses and the fair value of stock-based awards issued.</span></div>
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.5
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. These financial instruments are primarily held at two U.S. financial institutions that management believes are of high credit quality. Recursion’s primary bank accounts significantly exceed the federally insured limits. </span></div>The Company is dependent on third-party suppliers for certain research and development activities including preclinical and clinical testing. In particular, the Company relies and expects to continue to rely on a small number of these suppliers. These activities could be adversely affected by a significant interruption to Recursion’s third-party suppliers including a delay in the Company’s preclinical and clinical testing and the supply of certain consumable products and compounds.
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	83462000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	35929000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18737000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9962000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64725000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25967000	USD
CY2021	us-gaap	Depreciation Depreciation	8800000	USD
CY2020	us-gaap	Depreciation Depreciation	4200000	USD
CY2019	us-gaap	Depreciation Depreciation	3500000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11738000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3085000	USD
CY2021Q4	rxrx	Accrued Development Costs Current AccruedDevelopmentCostsCurrent	4682000	USD
CY2020Q4	rxrx	Accrued Development Costs Current AccruedDevelopmentCostsCurrent	2289000	USD
CY2021Q4	rxrx	Accrued Early Discovery Expenses Current AccruedEarlyDiscoveryExpensesCurrent	2114000	USD
CY2020Q4	rxrx	Accrued Early Discovery Expenses Current AccruedEarlyDiscoveryExpensesCurrent	338000	USD
CY2021	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-2879000	USD
CY2021Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	4665000	USD
CY2020Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	0	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1793000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	734000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7341000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4039000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32333000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10485000	USD
CY2021	us-gaap	Interest Expense InterestExpense	2952000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1360000	USD
CY2019	us-gaap	Interest Expense InterestExpense	635000	USD
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	73000	USD
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	336000	USD
CY2019	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1741000	USD
CY2020	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-1024000	USD
CY2019	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1106000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	399503000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	129000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	399377000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	399377000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	34	position
CY2021	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	801000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	801000	USD
CY2021	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	911000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	430000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	481000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	911000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	126000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	785000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	904000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	904000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	904000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	904000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1815000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	430000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1385000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1815000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	126000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1689000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	304000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2021	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P2Y
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1600000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	90000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	97000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	105000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	114000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	124000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	193000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	723000	USD
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	6400000	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3700000	USD
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3700000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3977000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7053000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	7325000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	7513000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	7739000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	26448000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	60055000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	61200000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	36700000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	121434713	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	112088065	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	112088065	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	448312000	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	450850000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Subscribed But Unissued TemporaryEquitySharesSubscribedButUnissued	115598018	shares
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.5
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.5
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13830000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3836000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1385000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20937443	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.85
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12956000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3538555	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.79
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1266968	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.59
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4017316	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.30
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	36773000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19191714	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.78
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	260762000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7921361	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.89
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	121201000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.66
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.50
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.34
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	931000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	31700000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.04
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	47138000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	20707000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	15555000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-684000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	947000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1517000	USD
CY2021	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	149000	USD
CY2020	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2019	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-46603000	USD
CY2021	rxrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent	-0.011
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-21654000	USD
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-17072000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.032
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.033
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.036
CY2020	rxrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent	-0.010
CY2019	rxrx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Percent EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent	-0.015
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.004
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.011
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.238
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.252
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5922000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1906000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	76954000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43954000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1732000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	356000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	16742000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9529000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	3132000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1005000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1114000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	426000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	217000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	105913000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57076000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	102041000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55439000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3872000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1637000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2089000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1637000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1783000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3872000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1637000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55400000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	46600000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	21700000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	102000000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	353100000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	193800000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	63000000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	77400000	USD
CY2021Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	1900000	USD
CY2020Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	1100000	USD
CY2021	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	-172399000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-87006000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-61879000	USD
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21781386	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21781386	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21570265	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21570265	shares
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.99
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.99
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.87
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.87
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50148845	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	94438417	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	87515556	shares
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2021	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001601830-22-000012-index-headers.html	Edgar Link	pending
0001601830-22-000012-index.html	Edgar Link	pending
0001601830-22-000012.txt	Edgar Link	pending
0001601830-22-000012-xbrl.zip	Edgar Link	pending
exhibit1011-bayercollabora.htm	Edgar Link	pending
exhibit1015-industryoffi.htm	Edgar Link	pending
exhibit1015-industryoffi001.jpg	Edgar Link	pending
exhibit1015-industryoffi002.jpg	Edgar Link	pending
exhibit1015-industryoffi003.jpg	Edgar Link	pending
exhibit1015-industryoffi004.jpg	Edgar Link	pending
exhibit1015-industryoffi005.jpg	Edgar Link	pending
exhibit1015-industryoffi006.jpg	Edgar Link	pending
exhibit1015-industryoffi007.jpg	Edgar Link	pending
exhibit1015-industryoffi008.jpg	Edgar Link	pending
exhibit1015-industryoffi009.jpg	Edgar Link	pending
exhibit1015-industryoffi010.jpg	Edgar Link	pending
exhibit1015-industryoffi011.jpg	Edgar Link	pending
exhibit1015-industryoffi012.jpg	Edgar Link	pending
exhibit1015-industryoffi013.jpg	Edgar Link	pending
exhibit1015-industryoffi014.jpg	Edgar Link	pending
exhibit1015-industryoffi015.jpg	Edgar Link	pending
exhibit1015-industryoffi016.jpg	Edgar Link	pending
exhibit1015-industryoffi017.jpg	Edgar Link	pending
exhibit1015-industryoffi018.jpg	Edgar Link	pending
exhibit1015-industryoffi019.jpg	Edgar Link	pending
exhibit1015-industryoffi020.jpg	Edgar Link	pending
exhibit1015-industryoffi021.jpg	Edgar Link	pending
exhibit1015-industryoffi022.jpg	Edgar Link	pending
exhibit1015-industryoffi023.jpg	Edgar Link	pending
exhibit1015-industryoffi024.jpg	Edgar Link	pending
exhibit1015-industryoffi025.jpg	Edgar Link	pending
exhibit1015-industryoffi026.jpg	Edgar Link	pending
exhibit1015-industryoffi027.jpg	Edgar Link	pending
exhibit1015-industryoffi028.jpg	Edgar Link	pending
exhibit1015-industryoffi029.jpg	Edgar Link	pending
exhibit1015-industryoffi030.jpg	Edgar Link	pending
exhibit1015-industryoffi031.jpg	Edgar Link	pending
exhibit1015-industryoffi032.jpg	Edgar Link	pending
exhibit1015-industryoffi033.jpg	Edgar Link	pending
exhibit1015-industryoffi034.jpg	Edgar Link	pending
exhibit1015-industryoffi035.jpg	Edgar Link	pending
exhibit1015-industryoffi036.jpg	Edgar Link	pending
exhibit1015-industryoffi037.jpg	Edgar Link	pending
exhibit1015-industryoffi038.jpg	Edgar Link	pending
exhibit1015-industryoffi039.jpg	Edgar Link	pending
exhibit1015-industryoffi040.jpg	Edgar Link	pending
exhibit1015-industryoffi041.jpg	Edgar Link	pending
exhibit1015-industryoffi042.jpg	Edgar Link	pending
exhibit1015-industryoffi043.jpg	Edgar Link	pending
exhibit1015-industryoffi044.jpg	Edgar Link	pending
exhibit1015-industryoffi045.jpg	Edgar Link	pending
exhibit1015-industryoffi046.jpg	Edgar Link	pending
exhibit1015-industryoffi047.jpg	Edgar Link	pending
exhibit1015-industryoffi048.jpg	Edgar Link	pending
exhibit1015-industryoffi049.jpg	Edgar Link	pending
exhibit1015-industryoffi050.jpg	Edgar Link	pending
exhibit1015-industryoffi051.jpg	Edgar Link	pending
exhibit1015-industryoffi052.jpg	Edgar Link	pending
exhibit1015-industryoffi053.jpg	Edgar Link	pending
exhibit1015-industryoffi054.jpg	Edgar Link	pending
exhibit1015-industryoffi055.jpg	Edgar Link	pending
exhibit1015-industryoffi056.jpg	Edgar Link	pending
exhibit1015-industryoffi057.jpg	Edgar Link	pending
exhibit1015-industryoffi058.jpg	Edgar Link	pending
exhibit1015-industryoffi059.jpg	Edgar Link	pending
exhibit1015-industryoffi060.jpg	Edgar Link	pending
exhibit1015-industryoffi061.jpg	Edgar Link	pending
exhibit1015-industryoffi062.jpg	Edgar Link	pending
exhibit1015-industryoffi063.jpg	Edgar Link	pending
exhibit1015-industryoffi064.jpg	Edgar Link	pending
exhibit1015-industryoffi065.jpg	Edgar Link	pending
exhibit1015-industryoffi066.jpg	Edgar Link	pending
exhibit1015-industryoffi067.jpg	Edgar Link	pending
exhibit1015-industryoffi068.jpg	Edgar Link	pending
exhibit1015-industryoffi069.jpg	Edgar Link	pending
exhibit1015-industryoffi070.jpg	Edgar Link	pending
exhibit1015-industryoffi071.jpg	Edgar Link	pending
exhibit1015-industryoffi072.jpg	Edgar Link	pending
exhibit1015-industryoffi073.jpg	Edgar Link	pending
exhibit1015-industryoffi074.jpg	Edgar Link	pending
exhibit1015-industryoffi075.jpg	Edgar Link	pending
exhibit1015-industryoffi076.jpg	Edgar Link	pending
exhibit1015-industryoffi077.jpg	Edgar Link	pending
exhibit1015-industryoffi078.jpg	Edgar Link	pending
exhibit1015-industryoffi079.jpg	Edgar Link	pending
exhibit1015-industryoffi080.jpg	Edgar Link	pending
exhibit1015-industryoffi081.jpg	Edgar Link	pending
exhibit1015-industryoffi082.jpg	Edgar Link	pending
exhibit1015-industryoffi083.jpg	Edgar Link	pending
exhibit1015-industryoffi084.jpg	Edgar Link	pending
exhibit1015-industryoffi085.jpg	Edgar Link	pending
exhibit1015-industryoffi086.jpg	Edgar Link	pending
exhibit1015-industryoffi087.jpg	Edgar Link	pending
exhibit1015-industryoffi088.jpg	Edgar Link	pending
exhibit1015-industryoffi089.jpg	Edgar Link	pending
exhibit1015-industryoffi090.jpg	Edgar Link	pending
exhibit1015-industryoffi091.jpg	Edgar Link	pending
exhibit1015-industryoffi092.jpg	Edgar Link	pending
exhibit1015-industryoffi093.jpg	Edgar Link	pending
exhibit1015-industryoffi094.jpg	Edgar Link	pending
exhibit1015-industryoffi095.jpg	Edgar Link	pending
exhibit1015-industryoffi096.jpg	Edgar Link	pending
exhibit1015-industryoffi097.jpg	Edgar Link	pending
exhibit1025-rochecollabora.htm	Edgar Link	pending
exhibit108-vestarofficel.htm	Edgar Link	pending
exhibit108-vestarofficel001.jpg	Edgar Link	pending
exhibit108-vestarofficel002.jpg	Edgar Link	pending
exhibit108-vestarofficel003.jpg	Edgar Link	pending
exhibit108-vestarofficel004.jpg	Edgar Link	pending
exhibit108-vestarofficel005.jpg	Edgar Link	pending
exhibit108-vestarofficel006.jpg	Edgar Link	pending
exhibit108-vestarofficel007.jpg	Edgar Link	pending
exhibit108-vestarofficel008.jpg	Edgar Link	pending
exhibit108-vestarofficel009.jpg	Edgar Link	pending
exhibit108-vestarofficel010.jpg	Edgar Link	pending
exhibit108-vestarofficel011.jpg	Edgar Link	pending
exhibit108-vestarofficel012.jpg	Edgar Link	pending
exhibit108-vestarofficel013.jpg	Edgar Link	pending
exhibit108-vestarofficel014.jpg	Edgar Link	pending
exhibit108-vestarofficel015.jpg	Edgar Link	pending
exhibit108-vestarofficel016.jpg	Edgar Link	pending
exhibit108-vestarofficel017.jpg	Edgar Link	pending
exhibit108-vestarofficel018.jpg	Edgar Link	pending
exhibit108-vestarofficel019.jpg	Edgar Link	pending
exhibit108-vestarofficel020.jpg	Edgar Link	pending
exhibit108-vestarofficel021.jpg	Edgar Link	pending
exhibit108-vestarofficel022.jpg	Edgar Link	pending
exhibit108-vestarofficel023.jpg	Edgar Link	pending
exhibit108-vestarofficel024.jpg	Edgar Link	pending
exhibit108-vestarofficel025.jpg	Edgar Link	pending
exhibit108-vestarofficel026.jpg	Edgar Link	pending
exhibit108-vestarofficel027.jpg	Edgar Link	pending
exhibit108-vestarofficel028.jpg	Edgar Link	pending
exhibit108-vestarofficel029.jpg	Edgar Link	pending
exhibit108-vestarofficel030.jpg	Edgar Link	pending
exhibit108-vestarofficel031.jpg	Edgar Link	pending
exhibit108-vestarofficel032.jpg	Edgar Link	pending
exhibit108-vestarofficel033.jpg	Edgar Link	pending
exhibit108-vestarofficel034.jpg	Edgar Link	pending
exhibit108-vestarofficel035.jpg	Edgar Link	pending
exhibit108-vestarofficel036.jpg	Edgar Link	pending
exhibit108-vestarofficel037.jpg	Edgar Link	pending
exhibit108-vestarofficel038.jpg	Edgar Link	pending
exhibit108-vestarofficel039.jpg	Edgar Link	pending
exhibit108-vestarofficel040.jpg	Edgar Link	pending
exhibit108-vestarofficel041.jpg	Edgar Link	pending
exhibit108-vestarofficel042.jpg	Edgar Link	pending
exhibit108-vestarofficel043.jpg	Edgar Link	pending
exhibit108-vestarofficel044.jpg	Edgar Link	pending
exhibit108-vestarofficel045.jpg	Edgar Link	pending
exhibit108-vestarofficel046.jpg	Edgar Link	pending
exhibit108-vestarofficel047.jpg	Edgar Link	pending
exhibit108-vestarofficel048.jpg	Edgar Link	pending
exhibit108-vestarofficel049.jpg	Edgar Link	pending
exhibit108-vestarofficel050.jpg	Edgar Link	pending
exhibit108-vestarofficel051.jpg	Edgar Link	pending
exhibit108-vestarofficel052.jpg	Edgar Link	pending
exhibit108-vestarofficel053.jpg	Edgar Link	pending
exhibit108-vestarofficel054.jpg	Edgar Link	pending
exhibit108-vestarofficel055.jpg	Edgar Link	pending
exhibit108-vestarofficel056.jpg	Edgar Link	pending
exhibit108-vestarofficel057.jpg	Edgar Link	pending
exhibit108-vestarofficel058.jpg	Edgar Link	pending
exhibit108-vestarofficel059.jpg	Edgar Link	pending
exhibit108-vestarofficel060.jpg	Edgar Link	pending
exhibit108-vestarofficel061.jpg	Edgar Link	pending
exhibit108-vestarofficel062.jpg	Edgar Link	pending
exhibit108-vestarofficel063.jpg	Edgar Link	pending
exhibit108-vestarofficel064.jpg	Edgar Link	pending
exhibit108-vestarofficel065.jpg	Edgar Link	pending
exhibit108-vestarofficel066.jpg	Edgar Link	pending
exhibit108-vestarofficel067.jpg	Edgar Link	pending
exhibit108-vestarofficel068.jpg	Edgar Link	pending
exhibit108-vestarofficel069.jpg	Edgar Link	pending
exhibit108-vestarofficel070.jpg	Edgar Link	pending
exhibit108-vestarofficel071.jpg	Edgar Link	pending
exhibit108-vestarofficel072.jpg	Edgar Link	pending
exhibit108-vestarofficel073.jpg	Edgar Link	pending
exhibit108-vestarofficel074.jpg	Edgar Link	pending
exhibit108-vestarofficel075.jpg	Edgar Link	pending
exhibit108-vestarofficel076.jpg	Edgar Link	pending
exhibit108-vestarofficel077.jpg	Edgar Link	pending
exhibit108-vestarofficel078.jpg	Edgar Link	pending
exhibit108-vestarofficel079.jpg	Edgar Link	pending
exhibit108-vestarofficel080.jpg	Edgar Link	pending
exhibit108-vestarofficel081.jpg	Edgar Link	pending
exhibit108-vestarofficel082.jpg	Edgar Link	pending
exhibit108-vestarofficel083.jpg	Edgar Link	pending
exhibit108-vestarofficel084.jpg	Edgar Link	pending
exhibit108-vestarofficel085.jpg	Edgar Link	pending
exhibit108-vestarofficel086.jpg	Edgar Link	pending
exhibit108-vestarofficel087.jpg	Edgar Link	pending
exhibit108-vestarofficel088.jpg	Edgar Link	pending
exhibit108-vestarofficel089.jpg	Edgar Link	pending
exhibit108-vestarofficel090.jpg	Edgar Link	pending
exhibit108-vestarofficel091.jpg	Edgar Link	pending
exhibit108-vestarofficel092.jpg	Edgar Link	pending
exhibit108-vestarofficel093.jpg	Edgar Link	pending
exhibit108-vestarofficel094.jpg	Edgar Link	pending
exhibit108-vestarofficel095.jpg	Edgar Link	pending
exhibit108-vestarofficel096.jpg	Edgar Link	pending
exhibit108-vestarofficel097.jpg	Edgar Link	pending
exhibit108-vestarofficel098.jpg	Edgar Link	pending
exhibit108-vestarofficel099.jpg	Edgar Link	pending
exhibit108-vestarofficel100.jpg	Edgar Link	pending
exhibit108-vestarofficel101.jpg	Edgar Link	pending
exhibit108-vestarofficel102.jpg	Edgar Link	pending
exhibit108-vestarofficel103.jpg	Edgar Link	pending
exhibit108-vestarofficel104.jpg	Edgar Link	pending
exhibit108-vestarofficel105.jpg	Edgar Link	pending
exhibit108-vestarofficel106.jpg	Edgar Link	pending
exhibit108-vestarofficel107.jpg	Edgar Link	pending
exhibit108-vestarofficel108.jpg	Edgar Link	pending
exhibit108-vestarofficel109.jpg	Edgar Link	pending
exhibit108-vestarofficel110.jpg	Edgar Link	pending
exhibit108-vestarofficel111.jpg	Edgar Link	pending
exhibit108-vestarofficel112.jpg	Edgar Link	pending
exhibit108-vestarofficel113.jpg	Edgar Link	pending
exhibit108-vestarofficel114.jpg	Edgar Link	pending
exhibit108-vestarofficel115.jpg	Edgar Link	pending
exhibit108-vestarofficel116.jpg	Edgar Link	pending
exhibit108-vestarofficel117.jpg	Edgar Link	pending
exhibit108-vestarofficel118.jpg	Edgar Link	pending
exhibit108-vestarofficel119.jpg	Edgar Link	pending
exhibit108-vestarofficel120.jpg	Edgar Link	pending
exhibit108-vestarofficel121.jpg	Edgar Link	pending
exhibit108-vestarofficel122.jpg	Edgar Link	pending
exhibit108-vestarofficel123.jpg	Edgar Link	pending
exhibit108-vestarofficel124.jpg	Edgar Link	pending
exhibit108-vestarofficel125.jpg	Edgar Link	pending
exhibit108-vestarofficel126.jpg	Edgar Link	pending
exhibit108-vestarofficel127.jpg	Edgar Link	pending
exhibit108-vestarofficel128.jpg	Edgar Link	pending
exhibit108-vestarofficel129.jpg	Edgar Link	pending
exhibit211-10xk21.htm	Edgar Link	pending
exhibit231-eyconsentform10.htm	Edgar Link	pending
exhibit311-10xk21.htm	Edgar Link	pending
exhibit312-10xk21.htm	Edgar Link	pending
exhibit321-10xk21.htm	Edgar Link	pending
exhibit43-descriptionofsec.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rxrx-20211231.htm	Edgar Link	pending
rxrx-20211231.xsd	Edgar Link	pending
rxrx-20211231_cal.xml	Edgar Link	unprocessable
rxrx-20211231_def.xml	Edgar Link	unprocessable
rxrx-20211231_g1.jpg	Edgar Link	pending
rxrx-20211231_g10.jpg	Edgar Link	pending
rxrx-20211231_g11.jpg	Edgar Link	pending
rxrx-20211231_g12.jpg	Edgar Link	pending
rxrx-20211231_g13.jpg	Edgar Link	pending
rxrx-20211231_g14.jpg	Edgar Link	pending
rxrx-20211231_g15.jpg	Edgar Link	pending
rxrx-20211231_g16.jpg	Edgar Link	pending
rxrx-20211231_g17.jpg	Edgar Link	pending
rxrx-20211231_g18.jpg	Edgar Link	pending
rxrx-20211231_g19.jpg	Edgar Link	pending
rxrx-20211231_g2.jpg	Edgar Link	pending
rxrx-20211231_g20.jpg	Edgar Link	pending
rxrx-20211231_g21.jpg	Edgar Link	pending
rxrx-20211231_g22.jpg	Edgar Link	pending
rxrx-20211231_g23.jpg	Edgar Link	pending
rxrx-20211231_g24.jpg	Edgar Link	pending
rxrx-20211231_g25.jpg	Edgar Link	pending
rxrx-20211231_g26.jpg	Edgar Link	pending
rxrx-20211231_g27.jpg	Edgar Link	pending
rxrx-20211231_g28.jpg	Edgar Link	pending
rxrx-20211231_g29.jpg	Edgar Link	pending
rxrx-20211231_g3.jpg	Edgar Link	pending
rxrx-20211231_g30.jpg	Edgar Link	pending
rxrx-20211231_g31.jpg	Edgar Link	pending
rxrx-20211231_g32.jpg	Edgar Link	pending
rxrx-20211231_g33.jpg	Edgar Link	pending
rxrx-20211231_g34.jpg	Edgar Link	pending
rxrx-20211231_g35.jpg	Edgar Link	pending
rxrx-20211231_g36.jpg	Edgar Link	pending
rxrx-20211231_g37.jpg	Edgar Link	pending
rxrx-20211231_g38.jpg	Edgar Link	pending
rxrx-20211231_g39.jpg	Edgar Link	pending
rxrx-20211231_g4.jpg	Edgar Link	pending
rxrx-20211231_g40.jpg	Edgar Link	pending
rxrx-20211231_g41.jpg	Edgar Link	pending
rxrx-20211231_g42.jpg	Edgar Link	pending
rxrx-20211231_g43.jpg	Edgar Link	pending
rxrx-20211231_g44.jpg	Edgar Link	pending
rxrx-20211231_g45.jpg	Edgar Link	pending
rxrx-20211231_g46.jpg	Edgar Link	pending
rxrx-20211231_g47.jpg	Edgar Link	pending
rxrx-20211231_g48.jpg	Edgar Link	pending
rxrx-20211231_g49.jpg	Edgar Link	pending
rxrx-20211231_g5.jpg	Edgar Link	pending
rxrx-20211231_g50.jpg	Edgar Link	pending
rxrx-20211231_g51.jpg	Edgar Link	pending
rxrx-20211231_g52.jpg	Edgar Link	pending
rxrx-20211231_g53.jpg	Edgar Link	pending
rxrx-20211231_g54.jpg	Edgar Link	pending
rxrx-20211231_g55.jpg	Edgar Link	pending
rxrx-20211231_g56.jpg	Edgar Link	pending
rxrx-20211231_g57.jpg	Edgar Link	pending
rxrx-20211231_g58.jpg	Edgar Link	pending
rxrx-20211231_g59.jpg	Edgar Link	pending
rxrx-20211231_g6.jpg	Edgar Link	pending
rxrx-20211231_g60.jpg	Edgar Link	pending
rxrx-20211231_g61.jpg	Edgar Link	pending
rxrx-20211231_g62.jpg	Edgar Link	pending
rxrx-20211231_g63.jpg	Edgar Link	pending
rxrx-20211231_g64.jpg	Edgar Link	pending
rxrx-20211231_g65.jpg	Edgar Link	pending
rxrx-20211231_g66.jpg	Edgar Link	pending
rxrx-20211231_g67.jpg	Edgar Link	pending
rxrx-20211231_g68.jpg	Edgar Link	pending
rxrx-20211231_g69.jpg	Edgar Link	pending
rxrx-20211231_g7.jpg	Edgar Link	pending
rxrx-20211231_g70.jpg	Edgar Link	pending
rxrx-20211231_g71.jpg	Edgar Link	pending
rxrx-20211231_g72.jpg	Edgar Link	pending
rxrx-20211231_g73.jpg	Edgar Link	pending
rxrx-20211231_g74.jpg	Edgar Link	pending
rxrx-20211231_g75.jpg	Edgar Link	pending
rxrx-20211231_g8.jpg	Edgar Link	pending
rxrx-20211231_g9.jpg	Edgar Link	pending
rxrx-20211231_htm.xml	Edgar Link	completed
rxrx-20211231_lab.xml	Edgar Link	unprocessable
rxrx-20211231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RXRX
RECURSION PHARMACEUTICALS, INC. Stock $rxrx

2021 Form 10-K Financial Statement

#000160183022000012 Filed on March 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXRX RECURSION PHARMACEUTICALS, INC. Stock $rxrx

2021 Form 10-K Financial Statement

#000160183022000012 Filed on March 23, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RXRX
RECURSION PHARMACEUTICALS, INC. Stock $rxrx